Monthly Injectable Buprenorphine Cuts Relapse Risk by 3.5x, Studies Find

For decades, the standard approach to treating opioid use disorder with buprenorphine has required patients to take daily medication—typically a sublingual film or tablet dissolved under the tongue. This regimen, while effective for those who maintain it, creates inherent challenges. Patients must remember daily doses, secure steady supplies, and navigate pharmacy visits that can be stigmatizing or logistically difficult. Missed doses can lead to withdrawal symptoms and cravings, potentially triggering relapse.

Two new real-world studies published this month suggest that an alternative approach—monthly injectable extended-release buprenorphine—may dramatically improve outcomes while reducing healthcare costs. The findings add to a growing body of evidence supporting long-acting formulations as a valuable tool in the addiction treatment arsenal.

The Power of Persistence

The first study, published in Drug and Alcohol Dependence Reports, analyzed 12-month adherence patterns among 3,400 patients receiving medication-assisted treatment for opioid use disorder. Researchers compared outcomes for patients adherent to monthly injectable buprenorphine against those receiving other forms of medication-assisted treatment, including daily oral buprenorphine and methadone.

The results were striking. Patients who maintained adherence to monthly injectable buprenorphine were 3.5 to 8.1 times less likely to return to opioid use compared to patients on other medications—whether those comparison patients were adherent to their regimens or not.

"These data highlight the importance of how treatment delivery impacts outcomes for those living with opioid use disorder," said Ann Wheeler, PharmD, Vice President of Medical Affairs at Indivior, which manufactures the monthly injectable formulation marketed as Sublocade. "By improving continuity of care, monthly injectable buprenorphine treatment has the potential to reduce costly acute care utilization while supporting sustained recovery."

The study also identified factors associated with higher relapse risk across all treatment modalities: younger age, male sex, Medicaid coverage, urban residence, co-occurring alcohol or other substance use disorders, skin infections, and limited prior engagement with buprenorphine before initiating extended-release treatment. These findings suggest that patients with multiple risk factors may benefit particularly from the stability that monthly injections provide.

Health Beyond Abstinence

The second study, published in The Journal of Substance Use and Addiction Treatment, examined infectious disease outcomes and healthcare utilization patterns among 467 patients receiving monthly injectable buprenorphine compared to nearly 120,000 patients on daily oral buprenorphine.

Patients in the monthly injection group experienced a 62% reduction in bacteremia incidence—bloodstream infections that can become life-threatening and often require extended hospitalization. This dramatic difference likely reflects multiple factors: reduced injection drug use among patients achieving stable opioid agonist therapy, improved overall health and immune function, and better continuity of care.

Healthcare utilization patterns also favored the monthly injection group. During the six-month follow-up period, these patients had:

• 56% fewer inpatient hospital visits
• 22% fewer emergency department visits
• 21% fewer all-cause outpatient visits
• 77% fewer sexually transmitted infection-related outpatient visits

These reductions translate to substantial cost savings for healthcare systems and insurers, while also indicating improved quality of life for patients spending less time in medical facilities.

Why Monthly Formulations Matter

The superior performance of monthly injectable buprenorphine likely stems from several interconnected factors that address common barriers to recovery.

Elimination of daily decision-making removes the cognitive burden of remembering medication. For people whose lives have been destabilized by addiction, simplifying treatment to a monthly medical appointment can be transformative. The injection provides steady medication levels without the peaks and troughs that can occur with daily dosing.

Reduced stigma exposure matters enormously. Daily pharmacy visits for addiction medication can subject patients to judgmental treatment, uncomfortable questions, and the psychological weight of repeatedly identifying as someone in recovery. Monthly clinic visits feel more like standard medical care.

Protection during vulnerable periods is built into the formulation. Cravings and relapse risk often spike during stressful life events—job loss, relationship breakdowns, housing instability. Having medication already on board provides a buffer during these critical windows.

Improved clinician relationships develop when patients visit monthly for injections rather than interacting primarily through pharmacy transactions. These relationships can facilitate addressing co-occurring conditions, connecting patients with social services, and providing early intervention when problems emerge.

Access Remains Uneven

Despite the compelling evidence for monthly injectable buprenorphine, access remains limited for many patients who could benefit. The medication requires specialized training to administer, and not all addiction treatment providers offer it. Insurance coverage varies, with some plans imposing prior authorization requirements or quantity limits that create barriers.

Cost also plays a role. While long-acting formulations can reduce overall healthcare spending through fewer hospitalizations and emergency visits, the upfront medication costs are higher than generic daily buprenorphine. For uninsured patients or those with high-deductible plans, this can make monthly injections financially inaccessible despite their clinical advantages.

Geographic disparities compound these challenges. Rural areas, which often have shortages of addiction specialists, may lack any providers trained to administer extended-release buprenorphine. Patients in these areas face the frustrating paradox of having the greatest need for simplified treatment regimens while having the least access to them.

The Bigger Picture

These studies arrive at a pivotal moment for medication-assisted treatment policy in the United States. The DEA is preparing to implement new restrictions on telehealth prescribing of controlled substances, which could reduce access to buprenorphine initiation for patients in underserved areas. Meanwhile, debates continue about how best to deploy opioid settlement funds to expand treatment capacity.

The evidence suggests that investing in long-acting formulations should be part of any comprehensive strategy. This means training more providers in injection administration, working with insurers to remove coverage barriers, and ensuring that patients with the highest relapse risk factors have access to the most effective interventions.

For people struggling with opioid addiction, the message is hopeful: treatment options are improving, and sustained recovery is increasingly achievable. The 3.5 to 8.1 times reduction in relapse risk represents not just a statistical finding, but thousands of potential lives reclaimed—parents present for their children, workers returning to productivity, community members contributing rather than struggling.

The monthly injection won't be the right choice for everyone. Some patients prefer the control of daily dosing. Others have medical contraindications or simply respond better to alternative medications like methadone or naltrexone. But for those who choose it and can access it, extended-release buprenorphine appears to offer a powerful bridge from the chaos of active addiction to the stability of sustained recovery.

As the addiction treatment field continues evolving, studies like these provide crucial guidance for directing limited resources toward interventions with the strongest evidence base. In a crisis that has claimed too many lives, every advantage matters—and monthly injectable buprenorphine is proving to be a significant one.